Welcome
Welcome to the BIOSTAT-CHF website. On our website we publish information regarding the BIOSTAT-CHF project, its progress and regularly we publish any news regarding the project.
Please read below the latest news, as well as a description of the project.
1500 included, start of countdown
The 1500th patient was included in the index study. We have now started our countdown. Only 1000 more to go!
Brescia recruited 100th patient
On Tuesday the 14th of February, 2012, the study team in Brescia (Italy) were the first to recruit 100 patients in their BIOSTAT-CHF site. This is a very significant achievement.
The BIOSTAT-CHF Study Coordination Center would like to congratulate Prof.dr. Marco Metra and his entire study team with this achievement!
1000th patient in
2011 was a very succesful year. The recruitment target for that year was met and we nearly recruited a thousand patients in a single year.
As of January 5th 2012, the 1000th patient has been enrolled in Nancy, France.
All partners are thanked for their contribution!
First samples up for analysis!
The first samples were collected from different sites throughout Europe. In total samples were collected from 117 patients.
Part of these samples were already forwarded for analysis to the University of Leicester, to the team of Professor Ng.
100 patients in !
Already after a few months of recruitment, the 100th patient was enrolled.
First patient recruited!
In December 2010, in both The Netherlands (Groningen) and Norway (Stavanger) the first BIOSTAT-CHF patients were recruited! The study is now running!
The project
Heart Failure is common in Europe and its prevalence is increasing as our population ages. Despite major improvements in care since the early 90s, it is still related to poor prognosis, an impaired quality of life and high health care costs. Many new therapies have failed to further improve outcome. One obvious reason is that the response to treatment is not homogenous. Treatment may need to be tailored to the individual patient. BIOSTAT-CHF aims to identify patients with a poor outcome, despite currently recommended therapy using information on demographics, gender, existing biomarkers, genetics and proteomics. Both genomic and proteomic analyses recently underwent major technical improvements, resulting in genome-wide analyses and detection of low abundance proteins. In BIOSTAT-CHF an index cohort of 2500 patients with worsening heart failure, will be recruited. Treatment will be optimized according to the heart failure guidelines of the European Society of Cardiology with diuretics, ACE-inhibitors, betablockers and aldosterone antagonists. When patients are optimally treated, any change in symptoms and exercise tolerance will be evaluated. Patients will then be followed up for a mean of 18 months, and mortality and heart failure hospitalizations will be recorded. By using a systems biology approach, incorporating information from demographic, biomarker, genomic, proteomic and the initial response to therapy, a risk prediction model will be designed, identifying patients with a poor outcome on currently recommended therapy. This model will then be validated in a real-life cohort of 2500 heart failure patients. BIOSTAT-CHF will therefore be a major step towards personalized medicine. Identifying patients with a poor outcome on currently recommended therapy might lead to further development of targeted therapies, eventually leading to improvements in outcome for patients with heart failure in Europe.
Funding
The BIOSTAT-CHF study has become possible due to the FP7 Health grant that the European Union has made available.
FP7
The aim of the EU investment in Health research is to improve the health of European citizens, to address global health issues and to boost the competitiveness of European health-related industries. For detailed information, please refer to the Health Research website, or the CORDIS website.
